By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Biotech Inc. 

800 Ridgeview Drive

Horsham  Pennsylvania  19044  U.S.A.
Phone: 888-227-5624 Fax: n/a


Company News
Chengdu's HitGen Collaborates With Janssen Biotech (JNJ) On Oncology And Metabolics Discovery 10/4/2016 8:22:47 AM
Janssen Biotech (JNJ) Release: FDA Approves STELARA (ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn's Disease 9/26/2016 8:16:26 AM
Janssen Biotech (JNJ) Submits Application Seeking Approval Of Sirukumab In United States For Rheumatoid Arthritis 9/23/2016 8:29:29 AM
Janssen Biotech (JNJ) Submits Application To U.S. FDA To Expand Indication For Daratumumab (DARZALEX) 8/18/2016 6:47:40 AM
Carna Biosciences Cancels Deal With Janssen Biotech (JNJ) Due to Strategy Reasons 8/5/2016 6:11:35 AM
Janssen Biotech (JNJ) Announces Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Immuno-Oncology Combination In Lung Cancer 7/26/2016 6:26:16 AM
SoCal's Ionis Pharma (IONS) Cuts GI Deal Worth $810 Million With Janssen Biotech (JNJ) 7/19/2016 5:47:12 AM
Janssen Biotech Inc. (JNJ) To Present New Inflammatory Bowel Disease Data At Digestive Disease Week Meeting 5/16/2016 8:28:03 AM
Janssen Biotech Inc. (JNJ) Release: FDA Expands IMBRUVICA Label To Include New Data From Two Key Phase 3 Trials, Adding Overall Survival And Combination Data 5/9/2016 6:39:12 AM
MorphoSys AG Sues Janssen Biotech Inc. (JNJ) And Genmab A/S (GEN.CO) For Patent Infringement 4/4/2016 11:46:30 AM